Advertisement

Unexpected Para-aortic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: a Contraindication to Resection?

  • Ji Su Kim
  • Ho Kyoung Hwang
  • Woo Jung Lee
  • Chang Moo KangEmail author
Original Article

Abstract

Background

Margin-negative resection is the only cure for pancreatic cancer. However, para-aortic lymph node metastasis is considered a contraindication to curative resection in pancreatic cancer. To determine if there are long-term survival differences according to the presence or absence of para-aortic lymph node metastasis in patients undergoing pancreatectomy, we evaluated oncologic outcomes in resected pancreatic cancer with unexpected para-aortic lymph node metastasis confirmed on intraoperative frozen section biopsy.

Methods

We retrospectively investigated 362 patients with pathologically confirmed pancreatic ductal adenocarcinoma who underwent pancreatectomy between 1996 and 2016.

Results

Patients with a metastatic para-aortic lymph node had the poorest median disease-specific survival [hazard ratio 14, 95% confidence interval 10–19]. However, after chemotherapy, patients with a metastatic para-aortic lymph node had a much higher disease-specific survival rate (para-aortic lymph node+/postoperative chemotherapy− versus para-aortic lymph node+/postoperative chemotherapy+, P = 0.0003, adjusted P = 0.0015). Patients with a metastatic para-aortic lymph node who underwent postoperative chemotherapy had a similar survival benefit to patients with metastatic regional lymph node without para-aortic lymph node metastasis, regardless of postoperative chemotherapy (para-aortic lymph node+/postoperative chemotherapy+ versus regional lymph node+/postoperative chemotherapy−, P = 0.3047, adjusted P > 0.9999; para-aortic lymph node+/postoperative chemotherapy+ versus regional lymph node+/postoperative chemotherapy+, P = 0.0905, adjusted P = 0.4525).

Conclusions

Unexpected para-aortic lymph node metastasis on frozen section biopsy may no longer be a contraindication to curative resection in “resectable” pancreatic ductal adenocarcinoma, as long as postoperative adjuvant chemotherapy can be administered.

Keywords

Pancreatic cancer Resection margin Lymph nodes Adjuvant chemotherapy 

Notes

Acknowledgments

We wish to thank Mrs. Lee EJ and Mrs. Kim HY from the Department of Biomedical Systems Informatics, Yonsei University College of Medicine, for participating in this study. We would like to thank Editage (www.editage.co.kr) for English language editing.

Author Contributions

(I) Conception and design: Ji Su Kim, Chang Moo Kang, (II) Administrative support: Chang Moo Kang, (III) Provision of study material or patients: Ho Kyoung Hwang, Woo Jung Lee, Chang Moo Kang, (IV) Collection and assembly of data: Ji Su Kim, Chang Moo Kang, (V) Data analysis and interpretation: Ji Su Kim, Chang Moo Kang, (VI) Manuscript writing: All authors, (VII) Final approval of manuscript: All authors

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67(1):7-30.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Jung KW, Won YJ, Kong HJ, Lee ES, Community of Population-Based Regional Cancer R. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015. Cancer Res Treat 2018;50(2):303-316.CrossRefGoogle Scholar
  3. 3.
    Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995;221(1):59-66.CrossRefGoogle Scholar
  4. 4.
    Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 1996;223(3):273-279.CrossRefGoogle Scholar
  5. 5.
    Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244(1):10-15.CrossRefGoogle Scholar
  6. 6.
    Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I. An Evaluation of Radical Resection for Pancreatic-Cancer Based on the Mode of Recurrence as Determined by Autopsy and Diagnostic-Imaging. Cancer 1993;72(7):2118-2123.CrossRefGoogle Scholar
  7. 7.
    Connolly MM, Dawson PJ, Michelassi F, Moossa AR, Lowenstein F. Survival in 1001 patients with carcinoma of the pancreas. Ann Surg 1987;206(3):366-373.CrossRefGoogle Scholar
  8. 8.
    Shimada K, Sakamoto Y, Sano T, Kosuge T. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg 2006;203(3):345-352.CrossRefGoogle Scholar
  9. 9.
    Yoshida T, Matsumoto T, Sasaki A, Shibata K, Aramaki M, Kitano S. Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg 2004;187(6):736-740.CrossRefGoogle Scholar
  10. 10.
    Yamada S, Nakao A, Fujii T, Sugimoto H, Kanazumi N, Nomoto S, Kodera Y, Takeda S. Pancreatic cancer with paraaortic lymph node metastasis: a contraindication for radical surgery? Pancreas 2009;38(1):e13-17.CrossRefGoogle Scholar
  11. 11.
    Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res 2007;140(1):31-35.CrossRefGoogle Scholar
  12. 12.
    Kala Z, Valek V, Hlavsa J, Hana K, Vanova A. The role of CT and endoscopic ultrasound in pre-operative staging of pancreatic cancer. Eur J Radiol 2007;62(2):166-169.CrossRefGoogle Scholar
  13. 13.
    Imai H, Doi R, Kanazawa H, Kamo N, Koizumi M, Masui T, Iwanaga Y, Kawaguchi Y, Takada Y, Isoda H, Uemoto S. Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer. Int J Clin Oncol 2010;15(3):294-300.CrossRefGoogle Scholar
  14. 14.
    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3):267-277.CrossRefGoogle Scholar
  15. 15.
    Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009;101(6):908-915.CrossRefGoogle Scholar
  16. 16.
    Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei ACC, Raoul JL, Chone L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Jouffroy-Zeller C, Rat P, Castan F, Bachet JB. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Journal of Clinical Oncology 2018;36(18):LBA4001-LBA4001.CrossRefGoogle Scholar
  17. 17.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of U, Intergroup P. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-1825.CrossRefGoogle Scholar
  18. 18.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-1703.CrossRefGoogle Scholar
  19. 19.
    Chun YS, Pawlik TM, Vauthey JN. 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers. Ann Surg Oncol 2018;25(4):845-847.CrossRefGoogle Scholar
  20. 20.
    Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M, Andren-Sandberg A, Asbun HJ, Bockhorn M, Buchler MW, Conlon KC, Fernandez-Cruz L, Fingerhut A, Friess H, Hartwig W, Izbicki JR, Lillemoe KD, Milicevic MN, Neoptolemos JP, Shrikhande SV, Vollmer CM, Yeo CJ, Charnley RM, International Study Group on Pancreatic S. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 2014;156(3):591-600.CrossRefGoogle Scholar
  21. 21.
    Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, Andren-Sandberg A, Asbun HJ, Bassi C, Bockhorn M, Charnley R, Conlon KC, Dervenis C, Fernandez-Cruz L, Friess H, Gouma DJ, Imrie CW, Lillemoe KD, Milicevic MN, Montorsi M, Shrikhande SV, Vashist YK, Izbicki JR, Buchler MW, International Study Group on Pancreatic S. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 2014;156(1):1-14.CrossRefGoogle Scholar
  22. 22.
    Network NCC. Pancreatic Adenocarcinoma (Version 3.2019). 2019 [July 2, 2019]; Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
  23. 23.
    Choi SH, Kim SH, Choi JJ, Kang CM, Hwang HK, Lee WJ. Clinical necessity of the immunohistochemical reassessment of para-aortic lymph nodes in resected pancreatic ductal adenocarcinoma. Oncol Lett 2013;6(5):1189-1194.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Kurita A, Kodama Y, Nakamoto Y, Isoda H, Minamiguchi S, Yoshimura K, Kuriyama K, Sawai Y, Uza N, Hatano E, Uemoto S, Togashi K, Haga H, Chiba T. Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer. Gastrointest Endosc 2016;84(3):467-475.e461.CrossRefGoogle Scholar
  25. 25.
    Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg 2012;255(6):1048-1059.CrossRefGoogle Scholar
  26. 26.
    Winer J, Can MF, Bartlett DL, Zeh HJ, Zureikat AH. The current state of robotic-assisted pancreatic surgery. Nat Rev Gastroenterol Hepatol 2012;9(8):468-476.CrossRefGoogle Scholar
  27. 27.
    Fernandez-Cruz L, Cosa R, Blanco L, Levi S, Lopez-Boado MA, Navarro S. Curative laparoscopic resection for pancreatic neoplasms: a critical analysis from a single institution. J Gastrointest Surg 2007;11(12):1607-1621; discussion 1621-1602.CrossRefGoogle Scholar
  28. 28.
    Croome KP, Farnell MB, Que FG, Reid-Lombardo KM, Truty MJ, Nagorney DM, Kendrick ML. Total laparoscopic pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? Ann Surg 2014;260(4):633-638; discussion 638-640.CrossRefGoogle Scholar
  29. 29.
    Coolsen MM, van Dam RM, Chigharoe A, Olde Damink SW, Dejong CH. Improving outcome after pancreaticoduodenectomy: experiences with implementing an enhanced recovery after surgery (ERAS) program. Dig Surg 2014;31(3):177-184.CrossRefGoogle Scholar
  30. 30.
    Bai X, Zhang X, Lu F, Li G, Gao S, Lou J, Zhang Y, Ma T, Wang J, Chen W, Huang B, Liang T. The implementation of an enhanced recovery after surgery (ERAS) program following pancreatic surgery in an academic medical center of China. Pancreatology 2016;16(4):665-670.CrossRefGoogle Scholar
  31. 31.
    Gleeson FC, Levy MJ. Interventional Radiology for Pancreatic Cancer. Pancreatic Cancer. New York, NY: Springer New York, 2010, pp 859-894.CrossRefGoogle Scholar
  32. 32.
    Komo T, Murakami Y, Kondo N, Uemura K, Hashimoto Y, Nakagawa N, Urabe K, Takahashi S, Sueda T. Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2016;23(6):2019-2027.CrossRefGoogle Scholar
  33. 33.
    Sho M, Murakami Y, Motoi F, Satoi S, Matsumoto I, Kawai M, Honda G, Uemura K, Yanagimoto H, Kurata M, Fukumoto T, Akahori T, Kinoshita S, Nagai M, Nishiwada S, Unno M, Yamaue H, Nakajima Y. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. J Gastroenterol 2015;50(6):694-702.CrossRefGoogle Scholar
  34. 34.
    Murakami Y, Uemura K, Sudo T, Hashimoto Y, Yuasa Y, Sueda T. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg 2010;34(8):1900-1907.CrossRefGoogle Scholar
  35. 35.
    Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, Lin H, Vauthey JN, Pisters PW, Varadhachary GR, Wolff RA, Crane CH, Lee JE, Fleming JB. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol 2015;22(4):1168-1175.CrossRefGoogle Scholar
  36. 36.
    Kadera BE, Sunjaya DB, Isacoff WH, Li L, Hines OJ, Tomlinson JS, Dawson DW, Rochefort MM, Donald GW, Clerkin BM, Reber HA, Donahue TR. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA Surg 2014;149(2):145-153.CrossRefGoogle Scholar
  37. 37.
    Tran Cao HS, Zhang Q, Sada YH, Silberfein EJ, Hsu C, Van Buren G, 2nd, Chai C, Katz MHG, Fisher WE, Massarweh NN. Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery 2017;162(3):557-567.CrossRefGoogle Scholar
  38. 38.
    Fischer LK, Katz MH, Lee SM, Liu L, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Roland CL, Fleming JB, Estrella J, Rashid A, Wang H. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy. Histopathology 2016;68(2):210-220.CrossRefGoogle Scholar
  39. 39.
    Hashmi A, Kozick Z, Fluck M, Hunsinger MA, Wild J, Arora TK, Shabahang MM, Blansfield JA. Neoadjuvant versus Adjuvant Chemotherapy for Resectable Pancreatic Adenocarcinoma: A National Cancer Database Analysis. Am Surg 2018;84(9):1439-1445.PubMedGoogle Scholar
  40. 40.
    Orci LA, Meyer J, Combescure C, Buhler L, Berney T, Morel P, Toso C. A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford) 2015;17(7):565-572.CrossRefGoogle Scholar
  41. 41.
    Mirkin KA, Hollenbeak CS, Wong J. Greater lymph node retrieval and lymph node ratio impacts survival in resected pancreatic cancer. J Surg Res 2017;220:12-24.CrossRefGoogle Scholar
  42. 42.
    Ashfaq A, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg 2014;18(11):1929-1935.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  1. 1.Division of Hepatobiliary and Pancreatic Surgery, Department of SurgeryYonsei University College of MedicineSeoulKorea
  2. 2.Pancreatobiliary Cancer CenterYonsei Cancer Center, Severance HospitalSeoulKorea

Personalised recommendations